Interstitial Granulomatous Dermatitis as an Adverse Reaction to Vedolizumab.

Abstract	A 61-year-old woman with a medical history of ulcerative colitis (UC) developed an erythematous, mildly pruritic, maculopapular rash that was histologically consistent with reactive granulomatous dermatitis (RGD) with interstitial granulomatous dermatitis (IGD)-type features 1 week after vedolizumab infusion. Awareness of this complication is key to enhanced recognition and appropriate management as use of this medication becomes more prevalent.
Authors	Katherine G Beuerlein, Elise D Martin, Lindsay C Strowd
Journal	Cutis (Cutis) Vol. 109 Issue 3 Pg. 167-169 (Mar 2022) ISSN: 2326-6929 [Electronic] United States
PMID	35659138 (Publication Type: Case Reports, Journal Article)
Chemical References	Antibodies, Monoclonal, Humanized vedolizumab
Topics	Antibodies, Monoclonal, Humanized (adverse effects) Autoimmune Diseases Colitis, Ulcerative (drug therapy) Dermatitis (diagnosis, drug therapy, etiology) Female Granuloma (chemically induced, diagnosis) Humans Middle Aged

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!